Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.
You may also be interested in...
Antimicrobial Drug Approvals Should Include Pathogen-Specific Indications
FDA should be granted authority to approve antimicrobial drugs based on the pathogens they target rather than infection types.
Antimicrobial Drug Approvals Should Include Pathogen-Specific Indications
FDA should be granted authority to approve antimicrobial drugs based on the pathogens they target rather than infection types.
NCI/CMS Group Will Examine Coverage For Off-Label Cancer Drug Use
The collaboration between the National Cancer Institute and Centers for Medicare & Medicaid Services will work to formulate a policy that may be useful for commercial health insurance coverage of drugs, an NCI rep says.